Boehringer Ingelheim to expand US animal vaccine manufacturing sites

Boehringer Ingelheim has announced plans to expand its facilities in Athens, Georgia and St Joseph, Missouri to accommodate increased production of animal vaccines.

More than $80 million (59.89 million pounds) will be spent on the two projects, while the Athens site will grow from its current footprint of approximately 350,000 sq ft to 400,000 sq ft, nearly doubling its filling capacity for companion animal and avian vaccines.

Construction will begin in the fourth quarter of 2017 and will continue through to 2019, with commercial production anticipated to begin in the second half of 2019. An additional 50 positions will be added over the next three years to support the expansion.

Meanwhile, work on the St Joseph site will also begin in the fourth quarter, adding 13,000 sq ft of capacity to accommodate increased production of livestock animal vaccines sold worldwide. An additional 20 jobs will be created by the time the work is completed in late 2019.

Veronique Kodjo, global head of industrial operations for Boehringer Ingelheim's animal health business, said: "These significant investments in expansion and capacity ensure that we can continue to support our future business growth areas."

With over 20 years of experience within the animal health market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current animal health roles we have available, you can search for the latest job roles, register your details, or contact the team today.